Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo

Oncogene

Volumn 30, Issue 11, 2011, Pages 1341-1350

  Robinson, J P ^a   Vanbrocklin, M W ^a   Lastwika, K J ^a   McKinney, A J ^a   Brandner, S ^b   Holmen, S L ^a  

^a NEVADA CANCER INSTITUTE   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

AKT; glioma; Ink4a Arf; MEK; mouse model; targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ARF PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN KINASE B; RAF PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; GLIOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BENZAMIDES; BRAIN NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DIPHENYLAMINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENES, RAS; GLIOMA; HUMANS; IMIDAZOLES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES;

EID: 79952758949     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.513     Document Type: Article

References (35)

1. Balmanno K, Cook SJ. (2009). Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 16: 368-377.
2. Beier D, Rohrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P et al. (2008). Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 68: 5706-5715.
3. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A et al. (2009). Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4: e7752.
4. Chin L, Pomerantz J, DePinho RA. (1998). The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem Sci 23: 291-296. (Pubitemid 28461894)
5. Council NR, Research IoLA, Sciences CoL. (1996). Guide for the Care and Use of Laboratory Animals, 7th edn. National Academy Press: Washington, D.C., 140pp.
6. Federspiel M, Hughes S. (1997). Retroviral gene delivery. In: Emerson C, Sweeney H (eds). Methods in Cell Biology: Methods in Muscle Biology. Academic Press: San Diego, pp, 179-214. (Pubitemid 128787394)
7. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A et al. (2007). Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710. (Pubitemid 350070717)
8. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. (2000). Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25: 55-57. (Pubitemid 30257036)
9. Holmen SL, Williams BO. (2005). Essential role for Ras signaling in glioblastoma maintenance. Cancer Res 65: 8250-8255. (Pubitemid 41330589)
10. Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, Holland EC. (2005). mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 7: 356-368. (Pubitemid 40664225)
11. Ichimura K, Schmidt EE, Goike HM, Collins VP. (1996). Human glioblastomas with no alterations of the CDKN2A (p16INK4A, TS1) and CDK4 genes have frequent mutations of the retino-blastoma gene. Oncogene 13: 1065-1072. (Pubitemid 26329093)
12. Jiang BH, Aoki M, Zheng JZ, Li J, Vogt PK. (1999). Myogenic signaling of phosphatidylinositol 3-kinase requires the serinethreonine kinase Akt/protein kinase B. Proc Natl Acad Sci USA 96: 2077-2081. (Pubitemid 29117870)
13. Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K et al. (2008). Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68: 8673-8677.
14. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA et al. (1997). Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659. (Pubitemid 27513656)
15. Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM et al. (2009). NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 8: 2204-2210.
16. LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB et al. (2010). Phase I pharmacokinetic and pharma-codynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 16: 1924-1937.
17. Lyustikman Y, Momota H, Pao W, Holland EC. (2008). Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia 10: 501-510. (Pubitemid 351657392)
18. Mansour SJ, Candia JM, Matsuura JE, Manning MC, Ahn NG. (1996). Interdependent domains controlling the enzymatic activity of mito-gen-activated protein kinase kinase 1. Biochemistry 35: 15529-15536. (Pubitemid 26408891)
19. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. (1997). Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23: 35-61. (Pubitemid 27273454)
20. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
21. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. (1995). Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000. (Pubitemid 26006540)
22. Roberts PJ, Der CJ. (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310. (Pubitemid 46763022)
23. Robinson JP, Vanbrocklin MW, Guilbeault AR, Signorelli DL, Brandner S, Holmen SL. (2010). Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene 29: 335-344.
24. Roussel MF. (1999). The INK4 family of cell cycle inhibitors in cancer. Oncogene 18: 5311-5317. (Pubitemid 29462366)
25. Schaefer-Klein J, Givol I, Barsov EV, Whitcomb JM, VanBrocklin M, Foster DN et al. (1998). The EV-O-derived cell line DF-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors. Virology 248: 305-311. (Pubitemid 28417717)
26. Serrano M, Hannon GJ, Beach D. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707. (Pubitemid 24036021)
27. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466.
28. TCGA (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
29. Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC. (2002). Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res 62: 5551-5558.
30. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
31. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855-867. (Pubitemid 38410730)
32. Wang D, Boerner SA, Winkler JD, LoRusso PM. (2007). Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 1773: 1248-1255. (Pubitemid 47161034)
33. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM et al. (2009). PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69: 4286-4293.
34. Wellbrock C, Karasarides M, Marais R. (2004). The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5: 875-885. (Pubitemid 39486539)
35. Zhang Y, Xiong Y, Yarbrough WG. (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734. (Pubitemid 28155312)